Technical Analysis for RVNC - Revance Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.40 | 3.34% | 0.11 |
Earnings due: May 6
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Low | Weakness | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 3.34% | |
| New 52 Week Low | Weakness | 3.34% | |
| Wide Bands | Range Expansion | 3.34% | |
| Lower Bollinger Band Touch | Weakness | 3.34% | |
| Oversold Stochastic | Weakness | 3.34% | |
| New 52 Week Closing Low | Bearish | -4.76% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 23 hours ago |
| Outside Day | about 23 hours ago |
| Up 5% | about 23 hours ago |
| Up 3% | about 23 hours ago |
| Fell Below Previous Day's Low | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/06/2024
Revance Therapeutics, Inc. Description
Revance Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications worldwide. Its lead product candidate is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is based in Newark, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Drugs Pain Toxins Neuropathic Pain Headache Migraine Plastic Surgery Botulinum Toxin Botulism Migraine Headache Therapeutic Applications Neurotoxins Rhinitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 37.98 |
| 52 Week Low | 3.21 |
| Average Volume | 1,880,932 |
| 200-Day Moving Average | 10.00 |
| 50-Day Moving Average | 5.00 |
| 20-Day Moving Average | 4.07 |
| 10-Day Moving Average | 3.67 |
| Average True Range | 0.30 |
| RSI (14) | 28.06 |
| ADX | 28.92 |
| +DI | 13.47 |
| -DI | 33.92 |
| Chandelier Exit (Long, 3 ATRs) | 4.13 |
| Chandelier Exit (Short, 3 ATRs) | 4.11 |
| Upper Bollinger Bands | 4.95 |
| Lower Bollinger Band | 3.19 |
| Percent B (%b) | 0.12 |
| BandWidth | 43.24 |
| MACD Line | -0.45 |
| MACD Signal Line | -0.43 |
| MACD Histogram | -0.0285 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.93 | ||||
| Resistance 3 (R3) | 3.92 | 3.74 | 3.84 | ||
| Resistance 2 (R2) | 3.74 | 3.61 | 3.74 | 3.81 | |
| Resistance 1 (R1) | 3.57 | 3.52 | 3.66 | 3.58 | 3.78 |
| Pivot Point | 3.39 | 3.39 | 3.43 | 3.39 | 3.39 |
| Support 1 (S1) | 3.22 | 3.26 | 3.31 | 3.23 | 3.02 |
| Support 2 (S2) | 3.04 | 3.17 | 3.04 | 2.99 | |
| Support 3 (S3) | 2.87 | 3.04 | 2.96 | ||
| Support 4 (S4) | 2.88 |
